Abstract
Cytokine-based therapeutic approaches using interferon (IFN) and interleukin 2 (IL-2) were conventionally applied for the treatment of progressive RCC. Caused by the limited effectiveness of cytokine-based approaches in advanced renal cell carcinoma, new substances were needed. Among these, the “targeted therapies”, particularly the group of the tyrosine kinase inhibitors, are of main interest. At present, multikinase inhibitors and antiangiogenic agents (VEGFR, PDGFR-beta, and mTOR) are used in first- and second-line therapies of metastatic RCC in various clinical studies. This review presents and discusses the effectiveness of the most frequently used substances in mono- or combination regimes based on current data of the ASCO 2007.
Keywords: Renal cell carcinoma, tyrosine kinase inhibitor, antiangiogenic agents, ASCO 2007, combination regime, targeted therapies
Reviews on Recent Clinical Trials
Title: Novel Therapeutic Options in Metastatic Renal Cancer – Review and Post ASCO 2007 Update
Volume: 3 Issue: 3
Author(s): Stephan Kruck, Markus A. Kuczyk, Georgios Gakis, Mario W. Kramer, Arnulf Stenzl and Axel S. Merseburger
Affiliation:
Keywords: Renal cell carcinoma, tyrosine kinase inhibitor, antiangiogenic agents, ASCO 2007, combination regime, targeted therapies
Abstract: Cytokine-based therapeutic approaches using interferon (IFN) and interleukin 2 (IL-2) were conventionally applied for the treatment of progressive RCC. Caused by the limited effectiveness of cytokine-based approaches in advanced renal cell carcinoma, new substances were needed. Among these, the “targeted therapies”, particularly the group of the tyrosine kinase inhibitors, are of main interest. At present, multikinase inhibitors and antiangiogenic agents (VEGFR, PDGFR-beta, and mTOR) are used in first- and second-line therapies of metastatic RCC in various clinical studies. This review presents and discusses the effectiveness of the most frequently used substances in mono- or combination regimes based on current data of the ASCO 2007.
Export Options
About this article
Cite this article as:
Kruck Stephan, Kuczyk A. Markus, Gakis Georgios, Kramer W. Mario, Stenzl Arnulf and Merseburger S. Axel, Novel Therapeutic Options in Metastatic Renal Cancer – Review and Post ASCO 2007 Update, Reviews on Recent Clinical Trials 2008; 3 (3) . https://dx.doi.org/10.2174/157488708785700311
DOI https://dx.doi.org/10.2174/157488708785700311 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nucleosides, a Valuable Chemical Marker for Quality Control in Traditional Chinese Medicine Cordyceps
Recent Patents on Biotechnology β-Hydroxy-β-Methylbutyrate as a Countermeasure for Cancer Cachexia: A Cellular and Molecular Rationale
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in the Synthesis and Development of Curcumin, its Combinations and Formulations and Curcumin-like Compounds as Anti-infective Agents
Current Medicinal Chemistry Small Peptide and Protein-based Molecular Probes for Imaging Neurological Diseases
Current Protein & Peptide Science The Caveolin-1 Connection to Cell Death and Survival
Current Molecular Medicine Peptide-Drug Conjugate: A Novel Drug Design Approach
Current Medicinal Chemistry Rho Kinase and Angiogenesis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Increased Protein Oxidation and Loss of Protein-Bound Sialic Acid in Hepatic Tissues of D-galactose Induced Aged Rats
Current Aging Science Multiple Roles of Fibroblast Growth Factor 21 in Metabolism
Current Pharmaceutical Design The Role of Connexins in Carcinogenesis: Review of Current Knowledge
Current Signal Transduction Therapy Targeting Cyclooxygenase-2 in Hematological Malignancies: Rationale and Promise
Current Pharmaceutical Design Polymer-Based Drug Delivery Systems, Development and Pre-Clinical Status
Current Pharmaceutical Design PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay
Current Drug Targets Mitochondrial Tolerance to Drugs and Toxic Agents in Ageing and Disease
Current Drug Targets A Pan-Cancer Review of <i>ALK</i> Mutations: Implications for Carcinogenesis and Therapy
Current Cancer Drug Targets Polymeric Micelles for Ocular Delivery: Progress and Issues
Pharmaceutical Nanotechnology A Review on Synthetic and Natural Steroid Dimers: 1997-2006
Current Medicinal Chemistry Immunogenicity and Tumorigenicity of Pluripotent Stem Cells and their Derivatives: Genetic and Epigenetic Perspectives
Current Stem Cell Research & Therapy ANTI-ADHESION Evolves To a Promising Therapeutic Concept in Oncology
Current Medicinal Chemistry Pharmacology and Therapeutic Applications of Enediyne Antitumor Antibiotics
Current Molecular Pharmacology